2 completed, 1 terminated. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Terminated 1 |
Follow IntraBio Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T) IB1001 - Ataxia Telangiectasia | Phase 2 | Terminated | IntraBio Inc | 17 | 2020-01-08 | 2026-03-25 |
| N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC) IB1001 - Niemann-Pick Disease, Type C | Phase 2 | Completed | IntraBio Inc | 33 | 2019-09-04 | 2023-11-28 |
| N-Acetyl-L-Leucine for GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease) IB1001 - GM2 Gangliosidosis, Tay-Sachs Disease | Phase 2 | Completed | IntraBio Inc | 30 | 2019-06-07 | 2024-03-12 |
Ataxia Telangiectasia (1) · Gangliosidoses, GM2 (1) · Niemann-Pick Disease, Type C (1) · Sandhoff Disease (1) · Tay-Sachs Disease (1)
IB1001 (3) · acetylleucine (3)
Germany (3) · Spain (3) · United Kingdom (3) · United States (3) · Slovakia (1)
PMID 33482890, PMID 34349180, PMID 34387740, PMID 34620022, PMID 36456200, PMID 40739200, PMID 42467089